{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:23:33Z","timestamp":1769639013583,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2010,9,5]],"date-time":"2010-09-05T00:00:00Z","timestamp":1283644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1007\/s00520-010-0999-2","type":"journal-article","created":{"date-parts":[[2010,9,5]],"date-time":"2010-09-05T09:08:51Z","timestamp":1283677731000},"page":"1667-1674","source":"Crossref","is-referenced-by-count":24,"title":["How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?"],"prefix":"10.1007","volume":"19","author":[{"given":"Alexandre","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eng Hooi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,9,5]]},"reference":[{"key":"999_CR1","unstructured":"OSI P (2008) Tarceva\u00ae (Erlotinib) [package insert]. In Edition Melville, NY: Genentech"},{"key":"999_CR2","unstructured":"AstraZeneca (2005) Iressa\u00ae (Gefitinib) [package insert]. In Edition Wilmington, DE"},{"key":"999_CR3","unstructured":"GlaxoSmithKline (2008) Tykerb\u00ae (Lapatinib) [package insert]. In Edition Research Triangle Park, NC"},{"key":"999_CR4","unstructured":"Bayer HPI (2009) Nexavar\u00ae (Sorafenib) [package insert]. In Edition Wayne, NJ"},{"key":"999_CR5","unstructured":"Pfizer I (2008) Sutent\u00ae (Sunitinib) [package insert]. In Edition New York, NY"},{"key":"999_CR6","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.3816\/CLC.2006.s.009","volume":"8","author":"L Chou","year":"2007","unstructured":"Chou L, Garey J, Oishi K, Kim E (2007) Managing dermatologic toxicities of epidermal growth factor receptor inhibitors. Clin Lung Cancer 8:S15\u2013S22","journal-title":"Clin Lung Cancer"},{"key":"999_CR7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1634\/theoncologist.10-5-345","volume":"10","author":"R Perez-Soler","year":"2005","unstructured":"Perez-Soler R, Delord JP, Halpern A et al (2005) HER1\/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1\/EGFR inhibitor rash management forum. Oncologist 10:345\u2013356","journal-title":"Oncologist"},{"key":"999_CR8","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1634\/theoncologist.12-5-610","volume":"12","author":"TJ Lynch Jr","year":"2007","unstructured":"Lynch TJ Jr, Kim ES, Eaby B et al (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12:610\u2013621","journal-title":"Oncologist"},{"key":"999_CR9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3747\/co.v16i1.361","volume":"16","author":"B Melosky","year":"2009","unstructured":"Melosky B, Burkes R, Rayson D et al (2009) Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 16:14\u201324","journal-title":"Curr Oncol"},{"key":"999_CR10","unstructured":"National Cancer Institute (2009) Common terminology criteria for adverse events v4.0 In Edition 2009"},{"key":"999_CR11","unstructured":"Lacouture ME, Maitland ML, Segaert S et al (2009) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Supportive Care in Cancer, 1\u201314"},{"key":"999_CR12","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1345\/aph.1M241","volume":"43","author":"EH Tan","year":"2009","unstructured":"Tan EH, Chan A (2009) Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Pharmacother 43:1658\u20131666","journal-title":"Ann Pharmacother"},{"key":"999_CR13","unstructured":"Wolf SE (2009) Burns. In the merck manuals online medical library, Edition 2009"},{"key":"999_CR14","doi-asserted-by":"crossref","DOI":"10.1002\/9780470840481","volume-title":"Quality of life outcomes in clinical trials and health-care evaluation: a practical guide to analysis and interpretation","author":"SJ Walters","year":"2009","unstructured":"Walters SJ (2009) Quality of life outcomes in clinical trials and health-care evaluation: a practical guide to analysis and interpretation. Wiley, West Sussex"},{"key":"999_CR15","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1600-0625.2008.00715.x","volume":"17","author":"A Wollenberg","year":"2008","unstructured":"Wollenberg A, Moosmann N, Klein E, Katzer K (2008) A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol 17:790\u2013792","journal-title":"Exp Dermatol"},{"key":"999_CR16","first-page":"236","volume":"4","author":"ME Lacouture","year":"2006","unstructured":"Lacouture ME, Basti S, Patel J, Benson A (2006) The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol 4:236\u2013238","journal-title":"J Support Oncol"},{"key":"999_CR17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.critrevonc.2007.10.004","volume":"66","author":"C Gridelli","year":"2008","unstructured":"Gridelli C, Maione P, Amoroso D et al (2008) Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an experts panel meeting. Crit Rev Oncol Hematol 66:155\u2013162","journal-title":"Crit Rev Oncol Hematol"},{"key":"999_CR18","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/cncr.24120","volume":"115","author":"A Tejwani","year":"2009","unstructured":"Tejwani A, Wu S, Jia Y et al (2009) Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 115:1286\u20131299","journal-title":"Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-010-0999-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-010-0999-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-010-0999-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T02:02:02Z","timestamp":1559095322000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-010-0999-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,5]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["999"],"URL":"https:\/\/doi.org\/10.1007\/s00520-010-0999-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,5]]}}}